{"entity":{"id":"nct07632118","kind":"trial","name":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","aka":[],"tldr":"A phase 3 trial in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","summary":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery is a phase 3, randomised interventional study registered as NCT07632118 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 288 participants, started 2026-05-22 and due to reach its primary completion in 2029-05. Interventions recorded: Radiotherapy + GX; GX group. Conditions listed: Pancreatic Cancer. Primary outcome: DFS. Pancreatic eligibility wording from the registry: \"* Confirmed as pancreatic ductal adenocarcinoma by histopathology or cytology, with no evidence of distant metastasis confirmed by imaging\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07632118","url":"https://clinicaltrials.gov/study/NCT07632118"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","metastatic-pdac"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07632118","phase":"3","setting":"A Prospective, Multicenter, Randomized Controlled Phase III Study on Radiotherapy Combined With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","sponsor":"Tianjin Medical University Cancer Institute and Hospital","participation":[{"nct":"NCT07632118","source":"https://clinicaltrials.gov/study/NCT07632118","fetchedAt":"2026-10-07T16:55:52.872Z","studySha256":"c399315ef524cc7e84e5aeef76559d14b76d2fe50a17bb762de1f69583e026f3","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-08","leadSponsor":"Tianjin Medical University Cancer Institute and Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":288,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-05-22","startedType":"estimated","enrolled":288,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07632118/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}